Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
Article
PubMed
Google Scholar
Hur C, Miller M, Kong CY, Dowling EC, Nattinger KJ, Dunn M, Feuer EJ. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013;119(6):1149–58.
Article
PubMed
Google Scholar
National Cancer Institute Surveillance, Epidemiology, and End Results Program. https://seer.cancer.gov/. Accessed 16 Apr 2018.
Bass AJ, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B, Hinoue T, Laird PW, Curtis C, Shen H, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9.
Article
CAS
Google Scholar
Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21(5):449–56.
Article
PubMed
CAS
Google Scholar
Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta pathologica et microbiologica Scandinavica. 1965;64:31–49.
Article
PubMed
CAS
Google Scholar
Petrelli F, Berenato R, Turati L, Mennitto A, Steccanella F, Caporale M, Dallera P, de Braud F, Pezzica E, Di Bartolomeo M, et al. Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. J Gastrointest Oncol. 2017;8(1):148–63.
Article
PubMed
PubMed Central
Google Scholar
Normanno N, Bianco C, Strizzi L, Mancino M, Maiello MR, Luca AD, Caponigro F, Salomon DS. The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets. 2005;6(3):243–57.
Article
PubMed
CAS
Google Scholar
Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523–9.
Article
PubMed
CAS
Google Scholar
Okines AFC, Cunningham D. Trastuzumab in gastric cancer. Eur J Cancer. 2010;46(11):1949–59.
Article
PubMed
CAS
Google Scholar
Okines AFC, Thompson LC, Cunningham D, Wotherspoon A, Reis-Filho JS, Langley RE, Waddell TS, Noor D, Eltahir Z, Wong R, et al. Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann Oncol. 2013;24(5):1253–61.
Article
PubMed
CAS
Google Scholar
Barros-Silva JD, Leitao D, Afonso L, Vieira J, Dinis-Ribeiro M, Fragoso M, Bento MJ, Santos L, Ferreira P, Rego S, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer. 2009;100(3):487–93.
Article
PubMed
PubMed Central
CAS
Google Scholar
Press MF, Ellis CE, Gagnon RC, Grob TJ, Buyse M, Villalobos I, Liang Z, Wu S, Bang Y-J, Qin S-K, et al. HER2 status in advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma for entry to the TRIO-013/LOGiC trial of lapatinib. Mol Cancer Ther. 2017;16(1):228–38.
Article
PubMed
CAS
Google Scholar
Boers JE, Meeuwissen H, Methorst N. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology. 2011;58(3):383–94.
Article
PubMed
PubMed Central
Google Scholar
Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, Bangs CD, Cherry AM, Pai RK. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol. 2012;20(1):13–24.
Article
PubMed
CAS
PubMed Central
Google Scholar
Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, Chong JL, Lopez-Sanchez RI, Price T, Gladkov O, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476–84.
Article
PubMed
CAS
Google Scholar
Kim WH, Gomez-Izquierdo L, Vilardell F, Chu KM, Soucy G, Dos Santos LV, Monges G, Viale G, Brito MJ, Osborne S, et al. HER2 status in gastric and gastroesophageal junction cancer: results of the large, multinational HER-EAGLE study. Appl Immunohistochem Mol Morphol AIMM. 2018;26(4):239–45.
PubMed
CAS
Google Scholar
Fisher SB, Fisher KE, Squires MH, Patel SH, Kooby DA, El-Rayes BF, Cardona K, Russell MC, Staley CA, Farris AB, et al. HER2 in resected gastric cancer: is there prognostic value? J Surg Oncol. 2014;109(2):61–6.
Article
PubMed
Google Scholar
Begnami MD, Fukuda E, Fregnani JH, Nonogaki S, Montagnini AL, da Costa WL Jr., Soares FA. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol. 2011;29(22):3030–6.
Article
PubMed
CAS
Google Scholar
Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA international collaborative analysis. Ann Oncol. 2012;23(10):2656–62.
Article
PubMed
CAS
Google Scholar
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet (London, England). 2010;376(9742):687–97.
Article
CAS
Google Scholar
National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Gastric Cancer. https://www.nccn.org/professionals/physician_gls/PDF/gastric.pdf. Accessed 16 April 2018.
Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB 3rd, Carrato A, Gulley ML, Jain D, Kakar S, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2016;140(12):1345–63.
Article
PubMed
Google Scholar
Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet (London, England). 2014;383(9911):31–9.
Article
CAS
Google Scholar
Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–35.
Article
PubMed
CAS
Google Scholar
Fuchs CS, Tabernero J, Tomášek J, Chau I, Melichar B, Safran H, Tehfe MA, Filip D, Topuzov E, Schlittler L, et al. Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. Br J Cancer. 2016;115(8):974–82.
Article
PubMed
PubMed Central
CAS
Google Scholar
Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming XuJ, Peng Yong W, Langer B, Delmar P, Scherer SJ, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol. 2012;30(17):2119–27.
Article
PubMed
CAS
Google Scholar
Hacker UT, Escalona-Espinosa L, Consalvo N, Goede V, Schiffmann L, Scherer SJ, Hedge P, Van Cutsem E, Coutelle O, Buning H. Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial. Br J Cancer. 2016;114(8):855–62.
Article
PubMed
PubMed Central
CAS
Google Scholar
Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29(30):3968–76.
Article
PubMed
CAS
Google Scholar
Wang KL, Wu TT, Choi IS, Wang H, Resetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, et al. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer. 2007;109(4):658–67.
Article
PubMed
CAS
Google Scholar
Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M, Zamboli A, De Vita F, Galizia G. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol. 2008;15(1):69–79.
Article
PubMed
Google Scholar
Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):490–9.
Article
PubMed
CAS
Google Scholar
Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):481–9.
Article
PubMed
PubMed Central
CAS
Google Scholar
Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology. 2008;52(6):738–46.
Article
PubMed
CAS
Google Scholar
Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12(2):89–103.
Article
PubMed
CAS
Google Scholar
Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011;29(36):4803–10.
Article
PubMed
PubMed Central
CAS
Google Scholar
Panarese I, De Vita F, Ronchi A, Romano M, Alfano R, Di Martino N, Zito Marino F, Ferraraccio F, Franco R. Predictive biomarkers along gastric cancer pathogenetic pathways. Expert Rev Anticancer Ther. 2017;17(5):417–25.
Article
PubMed
CAS
Google Scholar
Cunningham D, Tebbutt NC, Davidenko I, Murad AM, Al-Batran S-E, Ilson DH, Tjulandin S, Gotovkin E, Karaszewska B, Bondarenko I, et al. Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. J Clin Oncol. 2015;33(15_suppl):4000.
Google Scholar
Shah MA, Bang YJ, Lordick F, Tabernero J, Chen M, Hack SP, Phan SC, Shames DS, Cunningham D. METGastric: a phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC). J Clin Oncol. 2015;33(15_suppl):4012.
Google Scholar
Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi ST, Siu HC, Deng S, Chu KM, Law S, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. 2014;46(6):573–82.
Article
PubMed
CAS
Google Scholar
Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, Tao J, Rajasegaran V, Heng HL, Deng N, Gan A, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet. 2012;44(5):570–4.
Article
PubMed
CAS
Google Scholar
Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, Stewart C, Bandla S, Imamura Y, Schumacher SE, Shefler E, et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013;45(5):478–86.
Article
PubMed
PubMed Central
CAS
Google Scholar
Wang K, Johnson A, Ali SM, Klempner SJ, Bekaii-Saab T, Vacirca JL, Khaira D, Yelensky R, Chmielecki J, Elvin JA, et al. Comprehensive genomic profiling of advanced esophageal squamous cell carcinomas and esophageal adenocarcinomas reveals similarities and differences. Oncologist. 2015;20(10):1132–9.
Article
PubMed
PubMed Central
CAS
Google Scholar
Secrier M, Li X, de Silva N, Eldridge MD, Contino G, Bornschein J, MacRae S, Grehan N, O’Donovan M, Miremadi A, et al. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet. 2016;48(10):1131–41.
Article
PubMed
PubMed Central
CAS
Google Scholar
Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ, Lee KW, Kim EH, Yim SY, Lee SH, et al. Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project. Clin Cancer Res. 2017;23(15):4441–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Naseem M, Barzi A, Brezden-Masley C, Puccini A, Berger MD, Tokunaga R, Battaglin F, Soni S, McSkane M, Zhang W, et al. Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev. 2018;66:15–22.
Article
PubMed
CAS
PubMed Central
Google Scholar
Genitsch V, Novotny A, Seiler CA, Kroll D, Walch A, Langer R. Epstein-barr virus in gastro-esophageal adenocarcinomas—single center experiences in the context of current literature. Front Oncol. 2015;5:73.
Article
PubMed
PubMed Central
Google Scholar
Camargo MC, Murphy G, Koriyama C, Pfeiffer RM, Kim WH, Herrera-Goepfert R, Corvalan AH, Carrascal E, Abdirad A, Anwar M, et al. Determinants of Epstein-Barr virus-positive gastric cancer: an international pooled analysis. Br J Cancer. 2011;105(1):38–43.
Article
PubMed
PubMed Central
CAS
Google Scholar
Chang MS, Uozaki H, Chong JM, Ushiku T, Sakuma K, Ishikawa S, Hino R, Barua RR, Iwasaki Y, Arai K, et al. CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. Clin Cancer Res. 2006;12(10):2995–3002.
Article
PubMed
CAS
Google Scholar
Shinozaki-Ushiku A, Kunita A, Fukayama M. Update on Epstein-Barr virus and gastric cancer. Int J Oncol. 2015;46(4):1421–34.
Article
PubMed
CAS
Google Scholar
Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang XY, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 2017;19(6):1189–201.
Article
PubMed
CAS
PubMed Central
Google Scholar
Gulley ML. Genomic assays for Epstein-Barr virus-positive gastric adenocarcinoma. Exp Mol Med. 2015;47:e134.
Article
PubMed
PubMed Central
CAS
Google Scholar
Pandya D, Mariani M, He SQ, Andreoli M, Spennato M, Dowell-Martino C, Fiedler P, Ferlini C. Epstein-Barr virus MicroRNA expression increases aggressiveness of solid malignancies. PLoS ONE. 2015;10(9):e0136058.
Article
PubMed
PubMed Central
CAS
Google Scholar
Velho S, Fernandes MS, Leite M, Figueiredo C, Seruca R. Causes and consequences of microsatellite instability in gastric carcinogenesis. World J Gastroenterol. 2014;20(44):16433–42.
Article
PubMed
PubMed Central
CAS
Google Scholar
Zou L, Wu YY, Ma K, Fan YW, Dong DF, Geng NY, Li EX. Molecular classification of esophagogastric junction carcinoma correlated with prognosis. Oncotargets Ther. 2017;10:4765–72.
Article
Google Scholar
Mathiak M, Warneke VS, Behrens HM, Haag J, Boger C, Kruger S, Rocken C. Clinicopathologic characteristics of microsatellite instable gastric carcinomas revisited: urgent need for standardization. Appl Immunohistochem Mol Morphol. 2017;25(1):12–24.
Article
PubMed
Google Scholar
Vranic S. Microsatellite instability status predicts response to anti-PD-1/PD-L1 therapy regardless the histotype: a comment on recent advances. Bosnian J Basic Med. 2017;17(3):274–5.
Google Scholar
Fuchs CS, Doi T, Jang RWJ, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, et al. KEYNOTE-059 cohort 1: efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. J Clin Oncol. 2017. https://doi.org/10.1200/JCO.2017.35.15_suppl.4003.
Article
PubMed
PubMed Central
Google Scholar
Choi YY, Kim H, Yang HK, Kim WH, Kim YW, Kook MC, Park YK, Kim HH, Lee HS, Lee KH, et al. Clinical impact of microsatellite instability in patients with stage II and III gastric cancer: results from the CLASSIC trial. J Clin Oncol. 2017. https://doi.org/10.1200/JCO.2017.35.15_suppl.4022.
Article
PubMed
Google Scholar
Corso G, Velho S, Paredes J, Pedrazzani C, Martins D, Milanezi F, Pascale V, Vindigni C, Pinheiro H, Leite M, et al. Oncogenic mutations in gastric cancer with microsatellite instability. Eur J Cancer. 2011;47(3):443–51.
Article
PubMed
CAS
Google Scholar
Park J, Yoo HM, Jang W, Shin S, Kim M, Kim Y, Lee SW, Kim JG. Distribution of somatic mutations of cancer-related genes according to microsatellite instability status in Korean gastric cancer. Medicine. 2017;96(25):e7224.
Article
PubMed
PubMed Central
CAS
Google Scholar
Gornalusse GG, Hirata RK, Funk SE, Riolobos L, Lopes VS, Manske G, Prunkard D, Colunga AG, Hanafi LA, Clegg DO, et al. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nat Biotechnol. 2017;35(8):765–72.
Article
PubMed
PubMed Central
CAS
Google Scholar
Liu JF, McCleland M, Stawiski EW, Gnad F, Mayba O, Haverty PM, Durinck S, Chen YJ, Klijn C, Jhunjhunwala S, et al. Integrated exome and transcriptome sequencing reveals ZAK isoform usage in gastric cancer. Nat Commun. 2014;5:3830.
Article
PubMed
CAS
Google Scholar
Lim B, Kim JH, Kim M, Kim SY. Genomic and epigenomic heterogeneity in molecular subtypes of gastric cancer. World J Gastroenterol. 2016;22(3):1190–201.
Article
PubMed
PubMed Central
CAS
Google Scholar
Katona BW, Rustgi AK. Gastric cancer genomics: advances and future directions. Cell Mol Gastroenter. 2017;3(2):211–7.
Article
Google Scholar
Zhou X, Zheng Y. Cell type-specific signaling function of RhoA GTPase: lessons from mouse gene targeting. J Biol Chem. 2013;288(51):36179–88.
Article
PubMed
PubMed Central
CAS
Google Scholar
Rocken C, Behrens HM, Boger C, Kruger S. Clinicopathological characteristics of RHOA mutations in a Central European gastric cancer cohort. J Clin Pathol. 2016;69(1):70–5.
Article
PubMed
CAS
Google Scholar
Kim J, Bowlby R, Mungall AJ, Robertson AG, Odze RD, Cherniack AD, Shih J, Pedamallu CS, Cibulskis C, Dunford A, et al. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169–75.
Article
CAS
Google Scholar
Porta R, Borea R, Coelho A, Khan S, Araujo A, Reclusa P, Franchina T, Van Der Steen N, Van Dam P, Ferri J, et al. FGFR a promising druggable target in cancer: molecular biology and new drugs. Crit Rev Oncol Hemat. 2017;113:256–67.
Article
Google Scholar
Ahn S, Lee J, Hong M, Kim ST, Park SH, Choi MG, Lee JH, Sohn TS, Bae JM, Kim S, et al. FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. Modern Pathol. 2016;29(9):1095–103.
Article
CAS
Google Scholar
Tokunaga R, Imamura Y, Nakamura K, Ishimoto T, Nakagawa S, Miyake K, Nakaji Y, Tsuda Y, Iwatsuki M, Baba Y, et al. Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma. Oncotarget. 2016;7(15):19748–61.
Article
PubMed
PubMed Central
Google Scholar
Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, Matsangou M, Costa R, Carneiro B, Villaflor VM, et al. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget. 2017;8(9):16052–74.
Article
PubMed
Google Scholar
Van Cutsem E, Bang YJ, Mansoor W, Petty RD, Chao Y, Cunningham D, Ferry DR, Smith NR, Frewer P, Ratnayake J, et al. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. Ann Oncol. 2017;28(6):1316–24.
Article
PubMed
Google Scholar
Yu Y. A new molecular classification of gastric cancer proposed by Asian Cancer Research Group (ACRG). Transl Gastrointest Cancer. 2016;5(1):55–7.
Google Scholar
Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9.
Article
CAS
Google Scholar
Ooi CH, Ivanova T, Wu J, Lee M, Tan IB, Tao J, Ward L, Koo JH, Gopalakrishnan V, Zhu Y, et al. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet. 2009;5(10):e1000676.
Article
PubMed
PubMed Central
CAS
Google Scholar
Chia NY, Tan P. Molecular classification of gastric cancer. Ann Oncol. 2016;27(5):763–9.
Article
PubMed
Google Scholar
Fuchs CS, Doi T, Jang RWJ, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, et al. KEYNOTE-059 cohort 1: efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. J Clin Oncol. 2017. https://doi.org/10.1200/JCO.2017.35.15_suppl.4003.
Article
PubMed
PubMed Central
Google Scholar
Wainberg ZA, Jalal S, Muro K, Yoon HH, Garrido M, Golan T, Doi T, Catenacci DV, Geva R, Ku G, et al. LBA28_PRKEYNOTE-059 Update: efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer. Ann Oncol. 2017. https://doi.org/10.1093/annonc/mdx440.020.
Article
PubMed
Google Scholar
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017. https://doi.org/10.1016/S0140-6736(17)31827-5.
Article
PubMed Central
PubMed
Google Scholar
Doi T, Piha-Paul SA, Jalal SI, Saraf S, Lunceford J, Koshiji M, Bennouna J. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma. J Clin Oncol. 2018;36(1):61–7.
Article
PubMed
Google Scholar
Ralph C, Elkord E, Burt DJ, O’Dwyer JF, Austin EB, Stern PL, Hawkins RE, Thistlethwaite FC. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res. 2010;16(5):1662–72.
Article
PubMed
CAS
Google Scholar
Moehler MH, Cho JY, Kim YH, et al. A randomized, openlabel, two-arm phase II trial comparing the efficacy of sequential ipilimumab (ipi) versus best supportive care (BSC) following first-line (1L) chemotherapy in patients with unresectable, locally advanced/metastatic (A/M) gastric or gastro-esophageal junction (G/GEJ) cancer. J Clin Oncol. 2016. https://doi.org/10.1200/JCO.2016.34.15_suppl.4011.
Article
Google Scholar
Ohtsu A, Tabernero J, Bang YJ, Fuchs CS, Sun L, Wang Z, Csiki I, Koshiji M, Cutsem EV. Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study. J Clin Oncol. 2016. https://doi.org/10.1200/jco.2016.34.4_suppl.tps183.
Article
PubMed
Google Scholar
Chung HC, Arkenau HT, Wyrwicz L, Oh DY, Lee KW, Infante JR, Lee SS, Lee J, Keilholz U, Mita AC, et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: analysis of safety and clinical activity. J Clin Oncol. 2016. https://doi.org/10.1200/JCO.2016.34.15_suppl.4009.
Article
PubMed Central
PubMed
Google Scholar
https://www.pfizer.com/news/press-release/press-release-detail/merck_kgaa_darmstadt_germany_and_pfizer_provide_update_on_phase_iii_javelin_gastric_300_study_in_patients_with_pre_treated_advanced_gastric_cancer. Accessed 16 Apr 2018.
Champiat S, Ferte C, Lebel-Binay S, Eggermont A, Soria JC. Exomics and immunogenics: bridging mutational load and immune checkpoints efficacy. Oncoimmunology. 2014;3(1):e27817.
Article
PubMed
PubMed Central
Google Scholar
Boger C, Behrens HM, Kruger S, Rocken C. The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: a future perspective for a combined gastric cancer therapy? Oncoimmunology. 2017;6(4):e1293215.
Article
PubMed
PubMed Central
Google Scholar
Murphy AG, Kelly RJ. The evolving role of checkpoint inhibitors in the management of gastroesophageal cancer. Hematol Oncol Clin North Am. 2017;31(3):485–98.
Article
PubMed
Google Scholar
Tran PN, Sarkissian S, Chao J, Klempner SJ. PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence. Gastrointest Cancer. 2017;7:1–11.
PubMed
PubMed Central
Google Scholar
Bonotto M, Garattini SK, Basile D, Ongaro E, Fanotto V, Cattaneo M, Cortiula F, Iacono D, Cardellino GG, Pella N, et al. Immunotherapy for gastric cancers: emerging role and future perspectives. Expert Rev Clin Pharmacol. 2017;10(6):609–19.
Article
PubMed
CAS
Google Scholar
Lordick F, Shitara K, Janjigian YY. New agents on the horizon in gastric cancer. Ann Oncol. 2017;28(8):1767–75.
Article
PubMed
CAS
Google Scholar
Joshi SS, Maron SB, Catenacci DV. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. Future Oncol. 2017. https://doi.org/10.2217/fon-2017-0436.
Article
PubMed
PubMed Central
Google Scholar
Satoh T, Xu RH, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN—a randomized, phase III study. J Clin Oncol. 2014;32(19):2039–49.
Article
PubMed
CAS
Google Scholar
Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, Jeziorski K, Shparyk Y, Hoff PM, Sobrero A, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC—a randomized phase III trial. J Clin Oncol. 2016;34(5):443–51.
Article
PubMed
CAS
Google Scholar
Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, Mansoor W, Chung HC, Bodoky G, Shitara K, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017;18(5):640–53.
Article
PubMed
CAS
Google Scholar
Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K, Song C, Wu H, Eng-Wong J, Kang YK. 616OPertuzumab (P)+ trastuzumab (H)+ chemotherapy (CT) for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (mGC/GEJC): final analysis of a Phase III study (JACOB). Ann Oncol. 2017. https://doi.org/10.1093/annonc/mdx369.
Article
PubMed
PubMed Central
Google Scholar
Kim J, Fox C, Peng S, Pusung M, Pectasides E, Matthee E, Hong YS, Do IG, Jang J, Thorner AR, et al. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. J Clin Investig. 2014;124(12):5145–58.
Article
PubMed
PubMed Central
Google Scholar
Kwak EL, Ahronian LG, Siravegna G, Mussolin B, Borger DR, Godfrey JT, Jessop NA, Clark JW, Blaszkowsky LS, Ryan DP, et al. Molecular heterogeneity and receptor coamplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer. Cancer Discov. 2015;5(12):1271–81.
Article
PubMed
PubMed Central
CAS
Google Scholar
Kim C, Lee C-K, Chon HJ, Kim JH, Park HS, Heo SJ, Kim HJ, Kim TS, Kwon WS, Chung HC, et al. PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer. Oncotarget. 2017;8(69):113494–501.
PubMed
PubMed Central
Google Scholar
Pietrantonio F, Fucà G, Morano F, Gloghini A, Corso S, Aprile G, Perrone F, De Vita F, Tamborini E, Tomasello G, et al. Biomarkers of primary resistance to trastuzumab in HER2-positive metastatic gastric cancer patients: the amnesia case-control study. Clin Cancer Res. 2018;24(5):1082–9.
Article
PubMed
CAS
Google Scholar
Pietrantonio F, Caporale M, Morano F, Scartozzi M, Gloghini A, Vita FD, Giommoni E, Fornaro L, Aprile G, Melisi D, et al. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: implication for further clinical research. Int J Cancer. 2016;139(12):2859–64.
Article
PubMed
CAS
Google Scholar
Janjigian YY, Sanchez-Vega F, Tuvy Y, et al. Emergence of RTK/RAS/PI3K pathway alterations in trastuzumab-refractory HER2-positive esophagogastric (EG) tumors. ASCO Meet Abstr. 2016;34:11608.
Google Scholar
Kim ST, Banks KC, Pectasides E, Kim SY, Kim K, Lanman RB, Talasaz A, An J, Choi MG, Lee JH, et al. Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients. Ann Oncol. 2018. https://doi.org/10.1093/annonc/mdy034.
Article
PubMed Central
PubMed
Google Scholar
Grillo F, Fassan M, Sarocchi F, Fiocca R, Mastracci L. HER2 heterogeneity in gastric/gastroesophageal cancers: from benchside to practice. World J Gastroenterol. 2016;22(26):5879–87.
Article
PubMed
PubMed Central
Google Scholar
Fazlollahi L, Remotti HE, Iuga A, Yang H-M, Lagana SM, Sepulveda AR. HER2 heterogeneity in gastroesophageal cancer detected by testing biopsy and resection specimens. Arch Pathol Lab Med. 2018;142(4):516–22.
Article
PubMed
Google Scholar
Boger C, Kruger S, Behrens HM, Bock S, Haag J, Kalthoff H, Rocken C. Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations. Ann Oncol. 2017;28(5):1005–14.
Article
PubMed
PubMed Central
CAS
Google Scholar
Gumusay O, Benekli M, Ekinci O, Baykara M, Ozet A, Coskun U, Demirci U, Uner A, Dursun A, Atak EY, et al. Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites. Jpn J Clin Oncol. 2015;45(5):416–21.
Article
PubMed
Google Scholar
Qiu Z, Sun W, Zhou C, Zhang J. HER2 expression variability between primary gastric cancers and corresponding lymph node metastases. Hepatogastroenterology. 2015;62(137):231–3.
PubMed
Google Scholar
Janjigian YY, Sanchez-Vega F, Jonsson P, Chatila WK, Hechtman JF, Ku GY, Riches JC, Tuvy Y, Kundra R, Bouvier N, et al. Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov. 2018;8(1):49–58.
Article
PubMed
CAS
Google Scholar
Pectasides E, Stachler MD, Derks S, Liu Y, Maron S, Islam M, Alpert L, Kwak H, Kindler H, Polite B, et al. Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma. Cancer Discov. 2018;8(1):37–48.
Article
PubMed
CAS
Google Scholar
Gao J, Wang H, Zang W, Li B, Rao G, Li L, Yu Y, Li Z, Dong B, Lu Z, et al. Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer. Cancer Sci. 2017;108(9):1881–7.
Article
PubMed
PubMed Central
CAS
Google Scholar
Wang H, Li B, Liu Z, Gong J, Shao L, Ren J, Niu Y, Bo S, Li Z, Lai Y, et al. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer. Eur J Cancer. 2018;88:92–100.
Article
PubMed
CAS
Google Scholar
Uchôa Guimarães CT, Ferreira Martins NN, da Silva Cristina, Oliveira K, Almeida CM, Pinheiro TM, Gigek CO, de Araújo Roberto, Cavallero S, Assumpção PP, Cardoso Smith MA, Burbano RR, et al. Liquid biopsy provides new insights into gastric cancer. Oncotarget. 2018;9(19):15144–56.
PubMed
PubMed Central
Google Scholar
Creemers A, Krausz S, Strijker M, van der Wel MJ, Soer EC, Reinten RJ, Besselink MG, Wilmink JW, van de Vijver MJ, van Noesel CJM, et al. Clinical value of ctDNA in upper-GI cancers: a systematic review and meta-analysis. Biochimica et Biophysica Acta. 2017;1868(2):394–403.
PubMed
CAS
Google Scholar
Lopez A, Harada K, Mizrak Kaya D, Dong X, Song S, Ajani JA. Liquid biopsies in gastrointestinal malignancies: when is the big day? Expert Rev Anticancer Ther. 2018;18(1):19–38.
Article
PubMed
CAS
Google Scholar
Azad TD, Chaudhuri A, Newman AM, Stehr H, Schroers-Martin J, Chabon JJ, Fang P, Qiao Y, Liao ZX, Komaki R, et al. Circulating tumor DNA analysis for outcome prediction in localized esophageal cancer. J Clin Oncol. 2017;35(15_suppl):4055.
Article
Google Scholar
Vedeld HM, Goel A, Lind GE. Epigenetic biomarkers in gastrointestinal cancers: the current state and clinical perspectives. Semin Cancer Biol. 2017. https://doi.org/10.1016/j.semcancer.2017.12.004.
Article
PubMed
PubMed Central
Google Scholar
Mi L, Ji X, Ji J. Prognostic biomarker in advanced gastric cancer. Transl Gastrointest Cancer. 2016;5(1):16–29.
CAS
Google Scholar
Mallick R, Patnaik SK, Wani S, Bansal A. A systematic review of esophageal MicroRNA markers for diagnosis and monitoring of Barrett’s esophagus. Dig Dis Sci. 2016;61(4):1039–50.
Article
PubMed
CAS
Google Scholar
Zhang S, Chen L, Jung EJ, Calin GA. Targeting microRNAs with small molecules: from dream to reality. Clin Pharmacol Ther. 2010;87(6):754–8.
Article
PubMed
CAS
Google Scholar
Shomron N. MicroRNAs and pharmacogenomics. Pharmacogenomics. 2010;11(5):629–32.
Article
PubMed
CAS
Google Scholar
Pichler M, Calin GA. MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients. Br J Cancer. 2015;113(4):569–73.
Article
PubMed
PubMed Central
CAS
Google Scholar
Zhang K, Wu X, Wang J, Lopez J, Zhou W, Yang L, Wang SE, Raz DJ, Kim JY. Circulating miRNA profile in esophageal adenocarcinoma. Am J Cancer Res. 2016;6(11):2713–21.
PubMed
PubMed Central
CAS
Google Scholar
Tan C, Qian X, Guan Z, Yang B, Ge Y, Wang F, Cai J. Potential biomarkers for esophageal cancer. SpringerPlus. 2016;5:467.
Article
PubMed
PubMed Central
CAS
Google Scholar
Wu HH, Lin WC, Tsai KW. Advances in molecular biomarkers for gastric cancer: miRNAs as emerging novel cancer markers. Expert Rev Mol Med. 2014;16:e1.
Article
PubMed
PubMed Central
CAS
Google Scholar
Liu H-S, Xiao H-S. MicroRNAs as potential biomarkers for gastric cancer. World J Gastroenterol WJG. 2014;20(34):12007–17.
Article
PubMed
CAS
Google Scholar
Shirmohammadi K, Sohrabi S, Jafarzadeh Samani Z, Effatpanah H, Yadegarazari R, Saidijam M. Evaluation of altered expression of miR-9 and miR-106a as an early diagnostic approach in gastric cancer. J Gastrointest Oncol. 2018;9(1):46–51.
Article
PubMed
PubMed Central
Google Scholar
Fassan M, Saraggi D, Balsamo L, Realdon S, Scarpa M, Castoro C, Coati I, Salmaso R, Farinati F, Guzzardo V, et al. Early miR-223 upregulation in gastroesophageal carcinogenesis. Am J Clin Pathol. 2017;147(3):301–8.
Article
PubMed
Google Scholar
Song H, Sun W, Ye G, Ding X, Liu Z, Zhang S, Xia T, Xiao B, Xi Y, Guo J. Long non-coding RNA expression profile in human gastric cancer and its clinical significances. J Transl Med. 2013;11(1):225.
Article
PubMed
PubMed Central
CAS
Google Scholar
Yang Z, Guo X, Li G, Shi Y, Li L. Long noncoding RNAs as potential biomarkers in gastric cancer: opportunities and challenges. Cancer Lett. 2016;371(1):62–70.
Article
PubMed
CAS
Google Scholar
Hao N-B, He Y-F, Li X-Q, Wang K, Wang R-L. The role of miRNA and lncRNA in gastric cancer. Oncotarget. 2017;8(46):81572–82.
Article
PubMed
PubMed Central
Google Scholar
Wang H, Lu J, Tang J, Chen S, He K, Jiang X, Jiang W, Teng L. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways. BMC Cancer. 2017;17:191.
Article
PubMed
PubMed Central
CAS
Google Scholar
Chen Z, Huang W, Tian T, Zang W, Wang J, Liu Z, Li Z, Lai Y, Jiang Z, Gao J, et al. Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer. J Hematol Oncol. 2018;11:20.
Article
PubMed
PubMed Central
Google Scholar